Loading clinical trials...
Loading clinical trials...
A Multi-arm Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3-K) Inhibitor BKM120 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib
Conditions
Interventions
STI571
BKM120
Locations
11
United States
Dana Farber Cancer Institute SC (2)
Boston, Massachusetts, United States
Seattle Cancer Care Alliance Onc
Seattle, Washington, United States
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Villejuif, France
Start Date
April 20, 2012
Primary Completion Date
July 29, 2016
Completion Date
July 29, 2016
Last Updated
December 21, 2020
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions